GW Pharma Ends FY16 with $483mm in Cash

GW Pharm

GW Pharmaceuticals plc Reports Fourth Quarter and Year-End 2016 Financial Results and Operational Progress

– Three Positive Phase 3 Epidiolex clinical trials reported in 2016 –
– NDA submission and launch preparation on track –
– Conference call today at 8:00 a.m. EST –

LONDON, Dec. 05, 2016 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (NASDAQ:GWPH) (GW, the Company or the Group), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced financial results for the fourth quarter and year-ended 30 September 2016.

In 2016 GW has completed three positive Phase 3 trials for Epidiolex in patients with two different rare treatment resistant forms of childhood-onset epilepsy and we are making good progress towards an NDA submission. Our sights are now focused on Epidiolex approval and accelerating our preparations for a highly successful launch. Our goal is to provide the children and their families suffering from these highly treatment-resistant forms of childhood-onset epilepsy with a much needed new prescription option as quickly as possible.

Justin gover gw pharma ceoJustin Gover, GW’s Chief Executive Officer


  • Epidiolex® (CBD) orphan epilepsy program in Dravet syndrome, Lennox-Gastaut Syndrome (LGS), Tuberous Sclerosis Complex (TSC) and infantile spasms (IS)
    • Phase 3 trials:
      • Positive results in a pivotal Phase 3 Dravet syndrome trial
      • Positive results in two pivotal Phase 3 LGS trials
      • Positive data presented at the American Epilepsy Society Annual Meeting
    • Regulatory:
      • Positive Dravet syndrome pre-NDA meeting held with FDA in July 2016
      • Positive CMC pre-NDA meeting held with FDA in November 2016
      • NDA submission for both Dravet and LGS indications expected at end of H1 2017, just 3 years since opening of IND
      • Preparations advancing for EU regulatory submission in H2 2017
    • Manufacturing scale-up:
      • Manufacturing scale-up on track to deliver significant commercial launch inventory
    • Expanded access program and open label extension:
      • 98% of patients who complete Phase 3 trials have entered long term extension
      • Over 1,000 patients now on Epidiolex treatment
      • NDA submission to include safey data from over 1,500 patients and over 400 patients with 1 year or more continuous exposure
      • Withdrawal rate in long term studies approx 20%
    • Commercial:
      • US commercial team build underway and pre-launch preparations advancing well
      • EU commercial team now being established
    • Additional indications:
      • Phase 3 trial in TSC ongoing
      • Two part Phase 3 trial in IS commenced in December 2016
    • Intellectual Property:
      • Patent portfolio being prosecuted with claims directed to the use of CBD in the treatment of epilepsy seizure subtypes and epilepsy syndromes
  • Advanced clinical programs in multiple cannabinoid pipeline product candidates:
    • CBDV Phase 2 partial-onset epilepsy study in adults ongoing. Part A complete and Part B underway with data expected mid-2017
    • CBDV pre-clinical research ongoing within field of autism spectrum disorders. Phase 2 trials expected to commence in Q3 2017
      • Orphan Drug Designation from FDA for CBDV for the treatment of Rett syndrome
    • Neonatal Hypoxic-Ischemic Encephalopathy (NHIE) intravenous CBD program
      • Phase 1 trial commenced in December 2016
      • Orphan Drug and Fast Track Designations granted from FDA and EMA
    • THC:CBD for the treatment of Recurrent Glioblastoma Multiforme (GBM)
      • Phase 1b/2a study completed — data expected Q1 2017
      • Orphan Drug Designation from FDA
    • Sativex® Phase 2 study in children with spasticity due to cerebral palsy completed — data expected Q1 2017


  • Revenue for the twelve months ended 30 September 2016 of £10.3 million ($13.3 million) compared to £28.5 million for the twelve months ended 30 September 2015.
  • Loss for the twelve months ended 30 September 2016 of £63.7 million ($82.2 million) compared to £44.6 million for the twelve months ended 30 September 2015.
  • Cash and cash equivalents at 30 September 2016 of £374.4 million ($483.4 million) compared to £234.9 million as at 30 September 2015.

Conference Call and Webcast Information

GW Pharmaceuticals will host a conference call and webcast to discuss the fourth quarter and year-end 2016 financial results today at 8:00 a.m.. To participate in the conference call, please dial 877-407-8133 (toll free from the U.S. and Canada) or 201-689-8040 (international). Investors may also access a live audio webcast of the call via the investor relations section of the Company’s website at A replay of the call will also be available through the GW website shortly after the call and will remain available for 90 days. Replay Numbers: (toll free):1-877-481-4010, (international):1-919-882-2331. For both dial-in numbers please use conference ID # 13650870.

About GW Pharmaceuticals plc

Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW is advancing an orphan drug program in the field of childhood epilepsy with a focus on Epidiolex® (cannabidiol), which is in Phase 3 clinical development for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, Tuberous Sclerosis Complex and Infantile Spasms. GW commercialized the world’s first plant-derived cannabinoid prescription drug, Sativex®, which is approved for the treatment of spasticity due to multiple sclerosis in 30 countries outside the United States. The Company has a deep pipeline of additional cannabinoid product candidates which includes compounds in Phase 1 and 2 trials for glioma, schizophrenia and epilepsy. For further information, please visit

Original press release:

Get ahead of the crowd by signing up for 420 Investor, the largest & most comprehensive premium subscription service for cannabis traders and investors since 2013.

Published by NCV Newswire
NCV Newswire
The NCV Newswire by New Cannabis Ventures aims to curate high quality content and information about leading cannabis companies to help our readers filter out the noise and to stay on top of the most important cannabis business news. The NCV Newswire is hand-curated by an editor and not automated in anyway. Have a confidential news tip? Get in touch.

Get Our Sunday Newsletter